SCHEMBL4100403

SCHEMBL4100403

C=C(C(=O)OC12CC3CC(C1)CC(OC(C)(C)CC)(C3)C2)C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32
TGM2 P21980 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116527 0.86 DPP8 (0.33) DPP8DPP9
SCHEMBL13994978 0.85 TGM2 (0.34) TGM2
SCHEMBL13866174 0.82 DPP4 (0.33) TGM2
SCHEMBL15182749 0.81
SCHEMBL5144548 0.79 TSHR (0.36) TGM2
SCHEMBL4863633 0.79 TGM2 (0.31) TGM2
SCHEMBL14210237 0.78 CYP17A1 (0.34) DPP8DPP9
SCHEMBL15182750 0.78
SCHEMBL14446201 0.78 PKM (0.34) DPP8DPP9TGM2
SCHEMBL3686165 0.78 PKM (0.34) DPP8DPP9TGM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156854-A1 ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2009-06-18 US disclosed
US-7528279-B2 Adamantane derivatives and process for producing the same IDEMITSU KOSAN CO., LTD. (JP) 2009-05-05 US disclosed
US-20070129532-A1 Adamantane derivatives and process for producing the same IDEMITSU KOSAN CO., LTD (JP) 2007-06-07 US disclosed
EP-1712542-A1 ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2006-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156854-A1 ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME ADH1A, ADH5, TAS1R2 DPP8 2184/4885DPP9 1134/4885TGM2 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.